Atlas of Genetics and Cytogenetics in Oncology and Haematology
MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived)
| Identity |
| HGNC (Hugo) | MYCN |
| Location | 2p24.1 |
| Location_base_pair | Starts at 16080685 and ends at 16082265 bp from pter ( according to hg19-Feb_2009) [Mapping] |
| Local_order | centromeric to DDX1 |
 | |
| MYCN (2p24) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics. Laboratories willing to validate the probes are welcome : contact rocchi@biologia.uniba.it | |
| DNA/RNA |
| Description | 3 exons |
| Protein |
| Description | 464 amino acids; contains a phosphorylation site, an acidic domain, an HLH motif, and a leucine zipper in C-term; forms heterodimers with MAX and recognize the core concensus sequence CACCTG |
| Expression | during fetal development |
| Localisation | nuclear |
| Function | probable transcription factor; possible role during tissue differentiation |
| Homology | with members of the myc family of helix-loop-helix transcription factors |
| Mutations |
| Somatic | amplification, either in extrachromosomal double minutes or in homogeneously staining regions within chromosomes (there is amplification when, for exemple, 10 to 1000 copies of a gene are present in a cell); found amplified in a variety of human tumors, in particular in and also in retinoblastoma, small cell lung carcinoma, astrocytoma; level of amplification related to the tumor progression; transgenic mice that overexpress MYCN in neuroectodermal cells develop neuroblastoma |
| Implicated in |
| Entity | neuroblastoma |
| Oncogenesis | MYCN amplification is found in 15% of neuroblastoma, is an adverse prognostic feature per se, and is often associated with other adverse features (older age, abdominal tumor, advanced disease, and high lactate dehydrogenase, ferritin, and neuron-specific enolase serum levels) |
| External links |
| Bibliography |
| Transposition and amplification of oncogene-related sequences in human neuroblastomas. |
| Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW |
| Cell. 1983 ; 35 (2 Pt 1) : 359-367. |
| PMID 6197179 |
| MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. |
| Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 ; 15 (1) : 85-93. |
| PMID 8996128 |
| Targeted expression of MYCN causes neuroblastoma in transgenic mice. |
| Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM |
| The EMBO journal. 1997 ; 16 (11) : 2985-2995. |
| PMID 9214616 |
| Targeted expression of MYCN causes neuroblastoma in transgenic mice. |
| Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM |
| The EMBO journal. 1997 ; 16 (11) : 2985-2995. |
| PMID 9214616 |
| REVIEW articles | automatic search in PubMed |
| Last year publications | automatic search in PubMed |
| Contributor(s) |
| Written | 03-1998 | Jean-Loup Huret |
| Citation |
| This paper should be referenced as such : |
| Huret JL . MYCN (myc myelocytomatosis viral related oncogene, neuroblastoma derived). Atlas Genet Cytogenet Oncol Haematol. March 1998 . URL : http://AtlasGeneticsOncology.org/Genes/NMYC112.html |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Tue Aug 31 20:11:05 CEST 2010 |
For comments and suggestions or contributions, please contact us